Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers

Clicks: 277
ID: 6190
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #899 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Moxalactam is not more active on extended spectrum beta-lactamase (ESBL) producing bacteria than on non-ESBL producers Bhoj R Singh Division of Epidemiology, ICAR-Indian Veterinary Research Institute, Izatnagar, IndiaDear editorIn a recently published article1 moxalactam has been claimed to be very effective on extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae, concluding “MOX demonstrated excellent bactericidal effect, which is worthy of further exploration to serve as an alternative therapeutic agent against ESBL-producing Enterobacteriaceae”. Similar claims have also been made earlier.2 Out of interest we examined antimicrobial sensitivity data with reference to sensitivity to moxalactam, carbapenem resistant, and extended-spectrum β-lactamase (EBSL) and metallo-β-lactamase (MBL) production, among clinically important bacteria from the last 6 years (2011–2017), available from the Division of Epidemiology at Indian Veterinary Research Institute, Izatnagar. The analysis (Figure 1) revealed that conclusions drawn earlier1,2 on the basis of a study on a few strains may not be valid. My analysis revealed that of the 3,242 bacteria tested in our laboratory, using Clinical and Laboratory Standards Institute3 guidelines, 50.6% were identified as ESBL producers. Observations further revealed that moxalactam was certainly a more effective antibiotic on clinically important bacteria than most of the extended spectrum β-lactam antibiotics but no significant difference was detected between ESBL and non-ESBL producer bacteria with respect to their sensitivity to carbapenem (meropenem, imipenem and ertapenem), moxalactam and aztreonam. However, non-ESBL producing bacteria were more often positive for MBL production (p
Reference Key
bhoj2018moxalactaminfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bhoj R Singh and
Journal Infection and drug resistance
Year 2018
DOI
10.2147/IDR.S163186
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.